AI
AERI

Atom Investors’s Aerie Pharmaceuticals AERI Stock Holding History

Atom Investors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-244,145
Closed -$7.21M – 468
2019
Q2 		$7.21M Buy
244,145
+125,606
+106% +$4.84M 0.47% 68
2019
Q1 		$5.63M Buy
118,539
+23,823
+25% +$1.05M 0.48% 66
2018
Q4 		$3.42M Buy
+94,716
New +$4.44M 0.34% 62

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Atom Investors's AERI Position: Q3 2019 in Review

Atom Investors sold out of Aerie Pharmaceuticals (AERI) in Q3 2019, closing a stake of 244,145 shares — an estimated $7.21M sold.

Atom Investors first reported a position in AERI in Q4 2018 and held it in 3 quarters. The position peaked at $7.21M in Q2 2019. 167 funds tracked by Wall St. Rank hold AERI as of Q3 2019.

  • Atom Investors reported no remaining Aerie Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Atom Investors sold 244,145 Aerie Pharmaceuticals shares in Q3 2019, an estimated $7.21M.
  • Atom Investors first reported a position in Aerie Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Atom Investors's Aerie Pharmaceuticals position peaked at $7.21M in Q2 2019.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2019.

Based on Atom Investors's 13F filing for Q3 2019, filed 14 Nov 2019.